Johns Hopkins ABX Guide
Ceftazidime
INDICATIONS
FDA
FDA
- Lower respiratory tract infections including pneumonia caused by MSSA, S. pneumoniae, P. aeruginosa and other Pseudomonas spp., H. influenzae, Klebsiella spp., Enterobacter spp., P. mirabilis, E. coli, Serratia spp., and Citrobacter spp.
- Skin and skin-structure infections caused by MSSA, S. pyogenes, P. aeruginosa, Klebsiella spp., E. coli, Proteus spp. including P. mirabilisand indole-positive Proteus, Enterobacter spp., and Serratia spp.
- Complicated and uncomplicated urinary tract infections caused by P. aeruginosa, Enterobacter spp., Proteus spp., including P. mirabilis and indole-positive Proteus, Klebsiella spp. and E. coli
- Septicemia caused by S. pneumoniae, MSSA, P. aeruginosa, Klebsiella spp., H. influenzae, E. coli, and Serratia spp.
- Bone and joint infections caused by MSSA, P. aeruginosa, Klebsiella spp., and Enterobacter spp.
- Gynecologic infections (endometritis, pelvic cellulitis, and other GYN infections) caused by E. coli
- Intra-abdominal infections, including peritonitis caused by E. coli, Klebsiella spp.,, and MSSA, and polymicrobial infections caused by aerobic and anaerobic organisms including Bacteroides spp. (many B. fragilis strains are resistant)
- Central nervous system infections including meningitis, caused by H. influenzae and N. meningitidis. Has been successfully used in a limited number of meningitis cases caused by P. aeruginosa
- Note:
- Ceftazidime has substantially weaker Gram-positive activity than cefotaxime, ceftriaxone, or cefepime and is generally not selected for pneumococcal infection.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Healthcare-associated ventriculitis and meningitis or CSF shunt infections caused by susceptible Gram-negative bacilli, including P. aeruginosa.
- Melioidosis: intensive-phase treatment
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 6, 2026
Citation
Tsai, Y. V, and Kathryn Dzintars. "Ceftazidime." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime.
Tsai YV, Dzintars K. Ceftazidime. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime. Accessed September 22, 2026.
Tsai, Y. V., & Dzintars, K. (2026). Ceftazidime. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime
Tsai YV, Dzintars K. Ceftazidime [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 September 22]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ceftazidime
ID - 540101
A1 - Tsai,Y.,Pharm.D.
AU - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2026/09/06/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540101/all/Ceftazidime
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
